Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent

The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.

Related Keywords

,Samer Zeidan ,Yale School Of Medicine ,Bristol Myers Squibb ,International Prognostic Scoring System ,Yale Medical School ,Yale Cancer Center ,Yale Medical ,Yale School ,Imetelstat ,Mds ,Myelodysplastic Syndromes ,Yale Medicine ,Lancet ,Imerge ,